Sol-Gel Technologies Ltd.

SLGL

Healthcare Biotechnology

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024.

Revenue
−96.6%
EPS
−127.1%
Free cash flow
−8.76%

Quarter to June 2026, against a year earlier

61.01 2.00 −3.17%
Market cap
$199.8M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
6/9
Net debt / EBITDA
3.2×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(40.85%) (2.92%) (23.72%) (29.59%)

+8 more TTM periods

Piotroski F-Score
2 — 4 —
ROA
(35.11%) (2.44%) (18.63%) (23.17%)
ROIC
(6,630.24%) 0.00% 0.00% (122.92%)
Return on Tangible Assets
(35.30%) (2.11%) (29.26%) (35.03%)
Average Days of Receivables
144.98 21.09 37.05 189.45
Free Cash Flow per Share
(6.50) 0.00 (7.40) 0.00
Free Cash Flow
(21.27) — (20.61) —
Other line items

Show all line items

Columns are period end dates